A new study looking at the impact of ginger extract on the gut bacteria in people who have had a colonoscopy and had polyps removed is open in Mankato, Minnesota. This cancer prevention study, brought to Mayo Clinic Health System in Mankato through the Minnesota Cancer Clinical Trials Network (MNCCTN), is now open to eligible participants.
Based on research from the Masonic Cancer Center, University of Minnesota, and the Hormel Institute, the study examines the role of ginger on the gut microbiome. Researchers predict that the anti-inflammatory properties of ginger may impact the microbiome in a way that reduces a patient’s risk of colorectal cancer. The study will open in other MNCCTN locations across Minnesota shortly.
Over half of all Minnesotans will be diagnosed with cancer in their lifetimes. The Minnesota Cancer Clinical Trials Network (MNCCTN) is bringing cutting-edge cancer research from the state’s two NCI-designated Comprehensive Cancer Centers, the Mayo Clinic and Masonic Cancer Center, University of Minnesota, to greater Minnesota. Studies coming through MNCCTN aim to keep people from getting cancer, improve therapies for people with cancer, and improve life for cancer survivors.
MNCCTN’s partner healthcare organizations include Essentia Health, Sanford Health, Mayo Clinic Cancer Center, Metro-Minnesota Community Oncology Research Consortium, and Fairview Health System. With the help of these partners, the network has established 18 locations throughout Minnesota, with several more sites expected to open in subsequent years. MNCCTN reduces the patient’s burden of traveling and extra costs by bringing cancer clinical trials out of the Twin Cities’ metro and Rochester directly to communities.
To find available trials in your area, call the Nurse Navigator line at 612-624-2620. Eligibility criteria can be found at: https://clinicaltrials.gov/ct2/show/NCT03268655. To learn more about MNCCTN, visit mncancertrials.umn.edu.